The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.
Source link
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound
Date:
More like thisRelated
Jollibee Eyes Hong Kong as Listing Venue for Overseas Arm
The Philippines fast-food giant is considering listing its international...
Millions under severe weather threat over Labor Day weekend
IE 11 is not supported. For an optimal experience...
Storm chances continue for parts of New Mexico into next week
Slow-moving storms produced locally heavy rainfall across the state...